Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells

Cancer Prevention Research

Volumn 1, Issue 2, 2008, Pages 135-145

  Lu, Fang ^a   Zahid, Muhammad ^a   Wang, Cheng ^b   Saeed, Muhammad ^a   Cavalieri, Ercole L ^a   Rogan, Eleanor G ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; CYTOCHROME P 450 CYP1B1; CYTOCHROME P-450 CYP1B1; ESTRADIOL; NFE2L2 PROTEIN, HUMAN; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RESVERATROL; STILBENE DERIVATIVE; TRANSCRIPTION FACTOR NRF2; UNSPECIFIC MONOOXYGENASE;

ARTICLE; BIOLOGICAL MODEL; BREAST TUMOR; CELL LINE; CELL NUCLEUS; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; CHEMOPROPHYLAXIS; DNA ADDUCT; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PROTEIN TRANSPORT;

ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CELL LINE; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; DNA ADDUCTS; ESTRADIOL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MODELS, BIOLOGICAL; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; PROTEIN TRANSPORT; STILBENES; TETRACHLORODIBENZODIOXIN;

EID: 60549118140     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0037     Document Type: Article

References (47)

1. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427-33.
2. Dickson RB, Stancel GM. Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr 2000;27:135-45.
3. Cavalieri E, Chakravarti D, Guttenplan J, et al. Catechol estrogen quinones as initiators of breast and other human cancers: Implications for biomarkers of susceptibility and cancer prevention. Biochim BiophysActa-Rev Cancer 2006;1766:63-78.
4. Cavalieri E, Rogan E. Catechol quinones of estrogens in the initiation of breast, prostate and other human cancers. Ann N Y Acad Sci 2006;1089: 286-301.
5. Shimada T, HayesCL, Yamazaki H. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res1996;56:2979-84.
6. Talalay P, Dinkova-Kostova AT, Holtzclaw WD. Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis. Adv Enzyme Regul 2003; 43:121-34.
7. Hakkola J, Pasanen M, Pelkonen O, et al. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligandsin human placenta and cultured cells. Carcinogenesis 1997;18:391-7.
8. Muskhelishvili L, Thompson PA, Kusewitt DF, Wang C, Kadlubar FF. In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J Histochem Cytochem 2001;49:229-36.
9. Tang YM, Chen GF, Thompson PA, Lin DX, Lang NP, Kadlubar FF. Development of an antipeptide antibody that bindsto the C-terminal region of human CYP1B1. Drug Metab Dispos 1999;27: 274-80.
10. Carnell DM, Smith RE, Daley FM. Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int J Radiat Oncol Biol Phys2004;58:500-9.
11. Spink DC, HayesCL, Young NR, et al. The effects of 2,3,7,8- tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17 β-estradiol 4-hydroxylase. J Steroid Biochem Mol Biol 1994;51:251-8.
12. HayesCL, Spink DC, Spink BC. 17β-Estradiol hydroxylation catalyzed by human P450 1B1. Proc Natl Acad Sci U S A 1996;93:9776-81.
13. Gaikwad NW, Rogan EG, Cavalieri EL. Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones. Free Radic Biol Med 2007; 43:1289-98.
14. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet Med 2005;7:463-78.
15. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15: 979-87.
16. Park SJ, Zhao H, Spitz MR, Grossman HB, Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 2003; 536:131-7.
17. Cavalieri EL, Kumar S, Todorovic R, Higginbotham S, Badawi AF, Rogan EG. Imbalance of estrogen homeostasis in kidney and liver of hamsters treated with estradiol: implications for estrogen-induced initiation of renal tumors. Chem Res Toxicol 2001; 14:1041-50.
18. Rogan EG, Badawi AF, Devanesan PD, et al. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkerso f susceptibility to cancer. Carcinogenesis 2003;24:697-702.
19. Vidal JD, Vandevoort CA, MarcusCB, Lazarewicz NR, Conley AJ. 2,3,7,8-Tetrachlorodibenzo-p-dioxin induces CYP1B1 expression in human luteinized granulosa cells. Arch Biochem Biophys 2005;439: 53-60.
20. Spink BC, Hussain MM, Katz BH, Eisele L, Spink DC. Transient induction of cytochromes P450 1A1 and 1B1 in MCF-7 human breast cancer cells by indirubin. Biochem Pharmacol 2003;66:2313-21.
21. Singh S, Chakravarti D, Edney JA, et al. Relative imbalances in the expression of estrogen-metabolizing enzymes in the breast tissue of women with breast carcinoma. Oncol Rep 2005;14:1091-6.
22. Jang M, Cai L, Udeani GO. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-20.
23. Surh Y-J. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-80.
24. Aziz MH, Kumar R, Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms [review]. Int J Oncol 2003;23:17-28.
25. Spink DC, Spink BC, Cao JQ, et al. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 1998;19:291-8.
26. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, Yokoi T. Human CYP1B1 isregulated by estradiol via estrogen receptor. Cancer Res 2004;64: 3119-25.
27. Chen ZH, Hurh YJ, Na HK, et al. Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis 2004;25:2005-13.
28. Li Y, Cao Z, Zhu H. Upregulation of endogenous antioxidantsand phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol Res 2006; 53:6-15.
29. He X, Chen MG, Lin GX, Ma Q. Arsenic induces NAD(P)H-quinone oxidoreductase I by disrupting the Nrf2 × Keap1 × Cul3 complex and recruiting Nrf2 × Maf to the antioxidant response element enhancer. J Biol Chem 2006;18:23620-31.
30. YatesMS, Tauchi M, Katsuoka F, et al. Pharmacodynamic characterization of chemopreventive triterpenoidsas exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007;6: 154-62.
31. Warabi E, Takabe W, Minami T, et al. Shear stress stabilizes NF-E2-related factor 2 and induces antioxidant genesin endothelial cells: role of reactive oxygen/nitrogen species. Free Radic Biol Med 2007;15:260-9.
32. Stivala LA, Savio M, Carafoli F, et al. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effectsof resveratrol. J Biol Chem 2001;276:22586-94.
33. Zahid M, Gaikwad N, Cavalieri EL, Rogan EG. Inhibition of depurinating estrogen-DNA adducts by natural compounds. Chem Res Toxicol 2007;20: 1947-53.
34. Lu F, Zahid M, Saeed M, Cavalieri EL, Rogan EG. Estrogen metabolism and formation of estrogen-DNA adductsi n estradiol-treated MCF-10F cells. The effectso f TCDD induction and catechol-Omethyltransferase inhibition. J Steroid Biochem Mol Biol 2007;105:150-8.
35. Zahid M, Saeed M, Lu F, Gaikwad N, Cavalieri EL, Rogan EG. Inhibition of catechol-O-methyltransferase increases estrogen-DNA adduct formation. Free Radic Biol Med 2007;43: 1534-40.
36. Soule HD, Maloney TM, Wolman SR, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res1990;50:6075-86.
37. Russo J, Fernandez SV, Russo PA, et al. 17-β- Estradiol induces transformation and tumorigenesis in human breast epithelial cells. FASEB J 2006;20: 1622-34.
38. Wang C, Roy SK. Expression of growth differentiation factor 9 in the oocytesi s essential for the development of primordial folliclesin the hamster ovary. Endocrinology 2006;147:1725-34.
39. Zahid M, Kohli E, Saeed M, Rogan E, Cavalieri E. The greater reactivity of estradiol-3,4-quinone vses tradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity. Chem ResTox icol 2006; 19:164-72.
40. Fang JG, Lu M, Chen ZH, et al. Antioxidant effects of resveratrol and itsa naloguesa gainst the free-radical-induced peroxidation of linoleic acid in micelles. Chemistry 2002;8:4191-8.
41. Guengerich FP, Chun YJ, Kim D, Gillam EM, Shimada T. Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat Res 2003;523-4:173-82.
42. Ross D, Siegel S. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 2004;382: 115-44.
43. Numazawa S, Yoshida T. Nrf2-dependent gene expressions: a molecular toxicological aspect. J Toxicol Sci 2004;29:81-9.
44. Lee JM, Li J, Johnson DA, et al. Nrf2, a multiorgan protector? FASEB J 2005;19:1061-6.
45. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. GenesDev 1999; 13:76-86.
46. Vargas MR, Pehar M, Cassina P, et al. Fibroblast growth factor-1 inducesheme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival. J Biol Chem 2005;280:25571-9.
47. Liu S, Lin YC. Transformation of MCF-10A human breast epithelial cells by zeranol and estradiol-17β. Breast J 2004;10:514-21.